-
1
-
-
0028153260
-
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design [see comments]
-
Chou T.C., Motzer R.J., Tong Y.et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth. a rational approach to clinical protocol design [see comments] J. Natl. Cancer Inst. 86:1994;1517-1524.
-
(1994)
J. Natl. Cancer Inst.
, vol.86
, pp. 1517-1524
-
-
Chou, T.C.1
Motzer, R.J.2
Tong, Y.3
-
3
-
-
0027999967
-
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
-
Miller A.A., Hargis J.B., Lilenbaum R.C.et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors. a cancer and leukemia group B study J. Clin. Oncol. 12:1994;2743-2750.
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 2743-2750
-
-
Miller, A.A.1
Hargis, J.B.2
Lilenbaum, R.C.3
-
4
-
-
10544249871
-
Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments]
-
Rowinsky E.K., Kaufmann S.H., Baker S.D.et al. Sequences of topotecan and cisplatin. phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments] J. Clin. Oncol. 14:1996;3074-3084.
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 3074-3084
-
-
Rowinsky, E.K.1
Kaufmann, S.H.2
Baker, S.D.3
-
5
-
-
0030720766
-
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
-
Raymond E., Burris H.A., Rowinsky E.K.et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann. Oncol. 8:1997;1003-1008.
-
(1997)
Ann. Oncol.
, vol.8
, pp. 1003-1008
-
-
Raymond, E.1
Burris, H.A.2
Rowinsky, E.K.3
-
6
-
-
0027082880
-
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
-
Masuda N., Fukuoka M., Takada M.et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 10:1992;1775-1780.
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 1775-1780
-
-
Masuda, N.1
Fukuoka, M.2
Takada, M.3
-
7
-
-
0035399156
-
Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: A phase I/II study
-
Bowman A., Rye T., Ross G.et al. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer. a phase I/II study J. Clin. Oncol. 19:2001;3255-3259.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3255-3259
-
-
Bowman, A.1
Rye, T.2
Ross, G.3
-
8
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A., Figer A., Seymour M.et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 2938-2947
-
-
De Gramont, A.1
Figer, A.2
Seymour, M.3
-
9
-
-
0033989203
-
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
-
Giacchetti S., Perpoint B., Zidani R.et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:2000;136-147.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 136-147
-
-
Giacchetti, S.1
Perpoint, B.2
Zidani, R.3
-
10
-
-
0030900145
-
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]
-
ten Bokkel Huinink W., Gore M., Carmichael J.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]. J. Clin. Oncol. 15:1997;2183-2193.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 2183-2193
-
-
Ten Bokkel Huinink, W.1
Gore, M.2
Carmichael, J.3
-
11
-
-
0034064719
-
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
-
Piccart M.J., Green J.A., Lacave A.J.et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer. a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18:2000;1193-1202.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 1193-1202
-
-
Piccart, M.J.1
Green, J.A.2
Lacave, A.J.3
-
12
-
-
0032803291
-
Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin
-
Lin X., Howell S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol. 56:1999;390-395.
-
(1999)
Mol. Pharmacol.
, vol.56
, pp. 390-395
-
-
Lin, X.1
Howell, S.B.2
-
13
-
-
0033002906
-
Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors: Results of two independent phase I pharmacokinetic studies
-
Wasserman E., Cuvier C., Lokiec F.et al. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors. results of two independent phase I pharmacokinetic studies J. Clin. Oncol. 17:1999;1751-1759.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1751-1759
-
-
Wasserman, E.1
Cuvier, C.2
Lokiec, F.3
-
14
-
-
0033637555
-
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients
-
Goldwasser F., Gross-Goupil M., Tigaud J.M.et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule. a phase I study in advanced gastrointestinal cancer patients Ann. Oncol. 11:2000;1463-1470.
-
(2000)
Ann. Oncol.
, vol.11
, pp. 1463-1470
-
-
Goldwasser, F.1
Gross-Goupil, M.2
Tigaud, J.M.3
-
15
-
-
0029034767
-
High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma
-
Rosing H., Doyle E., Davies B.E.et al. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B. 668:1995;107-115.
-
(1995)
J Chromatogr B
, vol.668
, pp. 107-115
-
-
Rosing, H.1
Doyle, E.2
Davies, B.E.3
-
16
-
-
0019365237
-
Reporting results of cancer treatment
-
Miller A.B., Hoogstrater B., Staquet M.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
-
(1981)
Cancer
, vol.47
, pp. 207-214
-
-
Miller, A.B.1
Hoogstrater, B.2
Staquet, M.3
-
17
-
-
0021947525
-
A pronostic inflammatory and nutritional index scoring in critically ill patients
-
Ingelbleeck Y., Carpentier Y.A. A pronostic inflammatory and nutritional index scoring in critically ill patients. Int. J. Vit. Nutr. Res. 55:1985;91-101.
-
(1985)
Int. J. Vit. Nutr. Res.
, vol.55
, pp. 91-101
-
-
Ingelbleeck, Y.1
Carpentier, Y.A.2
-
18
-
-
0020131190
-
Comparison of nutritional indices and outcome of critically ill patients
-
Apelgren K., Rombeau J.L., Twomey P.L.et al. Comparison of nutritional indices and outcome of critically ill patients. Crit. Care Med. 10:1982;305-307.
-
(1982)
Crit. Care Med.
, vol.10
, pp. 305-307
-
-
Apelgren, K.1
Rombeau, J.L.2
Twomey, P.L.3
-
19
-
-
0022529253
-
Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition
-
Chang R.W., Jacobs S., Lee B. Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition. Lancet. 1:1986;1483-1486.
-
(1986)
Lancet
, vol.1
, pp. 1483-1486
-
-
Chang, R.W.1
Jacobs, S.2
Lee, B.3
-
20
-
-
0030716924
-
Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
-
Wasserman E., Myara A., Lokiec F.et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome. two case reports Ann. Oncol. 8:1997;1049-1051.
-
(1997)
Ann. Oncol.
, vol.8
, pp. 1049-1051
-
-
Wasserman, E.1
Myara, A.2
Lokiec, F.3
-
21
-
-
0034006524
-
Clinical pharmacokinetics of oxaliplatin: A critical review
-
Graham M.A., Lockwood G.F., Greenslade D.et al. Clinical pharmacokinetics of oxaliplatin. a critical review Clin Cancer Res. 6:2000;1205-1218.
-
(2000)
Clin Cancer Res.
, vol.6
, pp. 1205-1218
-
-
Graham, M.A.1
Lockwood, G.F.2
Greenslade, D.3
-
22
-
-
0028796513
-
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
-
van Warmerdam L.J., Verweij J., Schellens J.H.et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol. 35:1995;327-345.
-
(1995)
Cancer Chemother. Pharmacol.
, vol.35
, pp. 327-345
-
-
Van Warmerdam, L.J.1
Verweij, J.2
Schellens, J.H.3
-
23
-
-
15844424667
-
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
-
O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. 88:1996;817-824.
-
(1996)
J. Natl. Cancer Inst.
, vol.88
, pp. 817-824
-
-
O'Reilly, S.1
Rowinsky, E.2
Slichenmyer, W.3
-
24
-
-
0029966916
-
Phase I and pharmacologic study of topotecan in patients with impaired renal function
-
O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. 14:1996;3062-3073.
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 3062-3073
-
-
O'Reilly, S.1
Rowinsky, E.2
Slichenmyer, W.3
-
25
-
-
0026646768
-
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
-
Grochow L.B., Rowinsky E.K., Johnson R.et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 20:1992;706-713.
-
(1992)
Drug Metab. Dispos.
, vol.20
, pp. 706-713
-
-
Grochow, L.B.1
Rowinsky, E.K.2
Johnson, R.3
-
26
-
-
0032708102
-
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel - And platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
-
Ghamande S.A., Piver M.S. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel - and platinum-resistant recurrent ovarian or primary peritoneal cancer. a phase II pilot study J. Surg. Oncol. 72:1999;162-166.
-
(1999)
J. Surg. Oncol.
, vol.72
, pp. 162-166
-
-
Ghamande, S.A.1
Piver, M.S.2
-
27
-
-
0345059451
-
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
-
Herben V.M., Panday V.R., Richel D.J.et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J. Clin. Oncol. 17:1999;747-755.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 747-755
-
-
Herben, V.M.1
Panday, V.R.2
Richel, D.J.3
-
28
-
-
0034671437
-
Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
-
Hoskins P., Eisenhauer E., Vergote I.et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer. A National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 18:2000;4038-4044.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 4038-4044
-
-
Hoskins, P.1
Eisenhauer, E.2
Vergote, I.3
-
29
-
-
0026652640
-
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
-
Kaye S.B., Lewis C.R., Paul J.et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 340:1992;329-333.
-
(1992)
Lancet
, vol.340
, pp. 329-333
-
-
Kaye, S.B.1
Lewis, C.R.2
Paul, J.3
-
30
-
-
0033816778
-
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell ling cancer
-
Sorensen M., Jensen P.B., Herrstedt J.et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell ling cancer. Ann. Oncol. 11:2000;829-835.
-
(2000)
Ann. Oncol.
, vol.11
, pp. 829-835
-
-
Sorensen, M.1
Jensen, P.B.2
Herrstedt, J.3
-
31
-
-
0032925377
-
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
-
Gerrits C.J., Schellens J.H., Burris H.et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin. Cancer Res. 5:1999;69-75.
-
(1999)
Clin. Cancer Res.
, vol.5
, pp. 69-75
-
-
Gerrits, C.J.1
Schellens, J.H.2
Burris, H.3
-
32
-
-
0033729430
-
Population pharmacokinetics of topotecan: Intraindividual variability in total drug
-
Montazeri A., Boucaud M., Lokiec F.et al. Population pharmacokinetics of topotecan. intraindividual variability in total drug Cancer Chemother. Pharmacol. 46:2000;375-381.
-
(2000)
Cancer Chemother. Pharmacol.
, vol.46
, pp. 375-381
-
-
Montazeri, A.1
Boucaud, M.2
Lokiec, F.3
-
33
-
-
0032999031
-
Cellular pharmacology of the combination of oxaliplatine with oxaliplatin in the IGROV-1 human ovarian cancer cell line
-
Goldwasser F., Bozec L., Zeghari-Squalli N., Misset J.L. Cellular pharmacology of the combination of oxaliplatine with oxaliplatin in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs. 10:1999;195-201.
-
(1999)
Anticancer Drugs
, vol.10
, pp. 195-201
-
-
Goldwasser, F.1
Bozec, L.2
Zeghari-Squalli, N.3
Misset, J.L.4
-
34
-
-
0032905667
-
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 with the diaminocyclohexane platinum derivative oxaliplatin
-
Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 with the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. 5:1999;1189-1196.
-
(1999)
Clin. Cancer Res.
, vol.5
, pp. 1189-1196
-
-
Zeghari-Squalli, N.1
Raymond, E.2
Cvitkovic, E.3
Goldwasser, F.4
-
35
-
-
0032767121
-
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients
-
Goldwasser F., Buthaud X., Gross M.et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-Cancer Drugs. 10:1999;263-265.
-
(1999)
Anti-Cancer Drugs
, vol.10
, pp. 263-265
-
-
Goldwasser, F.1
Buthaud, X.2
Gross, M.3
|